Interpretation 2182
Tier 1|
|
|
Primary Sites
Tumor Types
Interpretation
Imatinib
Citations
- Blanke CD, et al. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol 2008;26(4):620-5
- Demetri GD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347(7):472-80
- Zalcberg JR, et al. Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg. Eur J Cancer 2005;41(12):1751-7
Last updated: 2018-04-18 13:05:06 UTC